NYSE:MNK Mallinckrodt (MNK) Stock Price, News & Analysis → Your $200 account credit is about to expire (From MarketBeat) (Ad) Free MNK Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.07▼$0.1350-Day Range$0.14▼$0.7552-Week Range$0.75▼$6.42Volume39,227 shsAverage Volume2.62 million shsMarket Capitalization$1.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisEarningsHeadlinesInsider TradesOwnershipSocial MediaStock AnalysisEarningsHeadlinesInsider TradesOwnershipSocial Media Get Mallinckrodt alerts: Email Address Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Mallinckrodt Stock (NYSE:MNK)Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.Read More Ad DTIWarning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation here MNK Stock News HeadlinesMarch 26, 2024 | finance.yahoo.comMallinckrodt plc Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides 2024 GuidanceMarch 4, 2024 | finanznachrichten.deMallinckrodt plc: Mallinckrodt Announces Appointment of Paul O'Neill as Executive Vice President, Quality & Operations, Specialty BrandsMarch 28, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.March 4, 2024 | finance.yahoo.comMallinckrodt Announces Appointment of Paul O'Neill as Executive Vice President, Quality & Operations, Specialty BrandsMarch 1, 2024 | markets.businessinsider.comMallinckrodt Says FDA Grants SNDA For Acthar Gel Single-Dose Pre-Filled SelfJect InjectorFebruary 24, 2024 | benzinga.comMallinckrodt Stock (OTC:MCKPF) Dividends: History, Yield and DatesFebruary 21, 2024 | finanznachrichten.deMallinckrodt plc: Mallinckrodt Presents Data on Real-World Outcomes with THERAKOS CELLEX Photopheresis System Treatment at the 2024 Tandem MeetingsFebruary 3, 2024 | msn.comMallinckrodt Announces Executive Appointments and Incentive PlansMarch 28, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… January 31, 2024 | morningstar.comMallinckrodt PLC Ordinary Shares - NewJanuary 9, 2024 | msn.comMallinckrodt to discontinue StrataGraft due to slow uptakeDecember 27, 2023 | finance.yahoo.comMallinckrodt Earns Top Score in Human Rights Campaign Foundation's 2023-2024 Corporate Equality IndexDecember 7, 2023 | sg.finance.yahoo.comMallinckrodt Announces FDA Clearance of the INOmax® EVOLVE™ DS Delivery System and Approval of the INOmax® (nitric oxide) Mini-CylinderDecember 1, 2023 | msn.comMallinckrodt Avoids $40 Million SEC Fine in Medicaid Overcharge CaseNovember 16, 2023 | finance.yahoo.comMallinckrodt plc (in Examinership) Reports Third Quarter 2023 Financial ResultsNovember 15, 2023 | msn.comMallinckrodt emerges from bankruptcyNovember 14, 2023 | finance.yahoo.comMallinckrodt Completes Financial Restructuring and Irish Examinership Proceedings and Emerges From Chapter 11October 11, 2023 | msn.comMallinckrodt sees emerging from Chapter 11 by end of yearOctober 11, 2023 | msn.comMallinckrodt Bankruptcy Plan Gets Approval, Will Wipe Out $1 Billion in Opioid PaymentsOctober 11, 2023 | finance.yahoo.comMallinckrodt Approved to End Bankruptcy, Reduce Opioid PaymentsOctober 10, 2023 | reuters.comMallinckrodt gets court approval for restructuring, $1 bln cut to opioid settlementOctober 10, 2023 | finance.yahoo.comMallinckrodt plc (in examinership) Receives U.S. Court Approval for Financial Restructuring PlanSeptember 20, 2023 | msn.comFirm Retention Summary: MallinckrodtSeptember 20, 2023 | msn.comDrug giant Mallinckrodt enters second Irish ExaminershipSeptember 19, 2023 | msn.comBankrupt Drugmaker Mallinckrodt Considers Sale of Opioid BusinessSeptember 1, 2023 | benzinga.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mallinckrodt plc (MNK)August 31, 2023 | finance.yahoo.comMallinckrodt Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD)See More Headlines Receive MNK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mallinckrodt and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/04/2020Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:MNK CUSIPN/A CIK1567892 Webwww.mallinckrodt.com Phone(531) 696-0000FaxN/AEmployees2,700Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($116.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net Margins-82.59% Pretax MarginN/A Return on Equity20.32% Return on Assets2.49% Debt Debt-to-Equity Ratio1.18 Current Ratio0.57 Quick Ratio0.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$47.48 per share Price / Book0.00Miscellaneous Outstanding Shares13,170,000Free Float13,131,000Market Cap$1.58 million OptionableNot Optionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMark C. TrudeauPresident, Chief Executive Officer & DirectorBryan M. ReasonsChief Financial Officer & Executive Vice PresidentSteven Joseph RomanoChief Scientific Officer & Executive VPBabatunde Adekunle OtulanaChief Medical Officer & Senior Vice PresidentMichele RobertsonChief Compliance Officer & Senior Vice PresidentKey CompetitorsSunshine BiopharmaNASDAQ:SBFMCyclacel PharmaceuticalsNASDAQ:CYCC60 Degrees PharmaceuticalsNASDAQ:SXTPHistogenNASDAQ:HSTODermata TherapeuticsNASDAQ:DRMAView All Competitors MNK Stock Analysis - Frequently Asked Questions How were Mallinckrodt's earnings last quarter? Mallinckrodt plc (NYSE:MNK) issued its quarterly earnings data on Tuesday, August, 4th. The company reported $1.89 EPS for the quarter, topping analysts' consensus estimates of $1.34 by $0.55. The firm earned $700.90 million during the quarter, compared to the consensus estimate of $630.19 million. Mallinckrodt had a positive trailing twelve-month return on equity of 20.32% and a negative net margin of 82.59%. The firm's revenue was down 14.9% on a year-over-year basis. During the same period in the prior year, the business earned $2.53 EPS. Read the conference call transcript. What other stocks do shareholders of Mallinckrodt own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mallinckrodt investors own include Gilead Sciences (GILD), Micron Technology (MU), Bausch Health Companies (BHC), Endo International (ENDP), Teva Pharmaceutical Industries (TEVA), Gerdau (GGB), AT&T (T), Alibaba Group (BABA), Advanced Micro Devices (AMD). This page (NYSE:MNK) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mallinckrodt plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.